Mediprint Ophthalmics has completed the first study in its SIGHT clinical program aimed at treating mild to moderate glaucoma and ocular hypertension. SIGHT-1 evaluated the company’s lead asset in human eyes for the first time. This initial trial achieved its objectives by showing a favorable safety and tolerability profile and extended beyond its intended aims by demonstrating an efficacy signal from a single dose.

In SIGHT-1, BMT1, a drug-eluting contact lens to treat glaucoma, was administered to 5 patients. The study subjects, who had not previously worn contact lenses, wore an LLT-BMT1 lens in each eye for 7 days continuously, during which the treatment regimen demonstrated 100% tolerability and no significant adverse events, confirming its safety profile. Bimatoprost is the FDA-cleared drug printed on the contact lens with the proprietary Mediprint process and, notably, the incidence of hyperemia detected in SIGHT-1 was lower than that observed for bimatoprost drops.

SIGHT-1 findings also included an efficacy signal from a single dose, which was not among the study design’s planned endpoints. However, this indicator encourages the company to proceed with SIGHT-2, a larger phase 2b dose-ranging clinical study intended to optimize dosage for efficacy.